A topography of immunotherapies against gastrointestinal malignancies.


Journal

Panminerva medica
ISSN: 1827-1898
Titre abrégé: Panminerva Med
Pays: Italy
ID NLM: 0421110

Informations de publication

Date de publication:
Mar 2022
Historique:
pubmed: 20 10 2021
medline: 7 4 2022
entrez: 19 10 2021
Statut: ppublish

Résumé

Gastrointestinal (GI) cancers are one of the leading causes of death worldwide. Although various approaches are implemented to improve the health condition of GI patients, none of the treatment protocols promise for eradicating cancer. However, a treatment mechanism against any kind of disease condition is already existing executing inside the human body. The 'immune system' is highly efficient to detect and destroy the unfavorable events of the body including tumor cells. The immune system can restrict the growth and proliferation of cancer. Cancer cells behave much smarter and adopt new mechanisms for hiding from the immune cells. Thus, cancer immunotherapy might play a decisive role to train the immune system against cancer. In this review, we have discussed the immunotherapy permitted for the treatment of GI cancers. We have discussed various methods and mechanisms, periodic development of cancer immunotherapies, approved biologicals, completed and ongoing clinical trials, role of various biopharmaceuticals, and epigenetic factors involved in GI cancer immunotherapies.

Identifiants

pubmed: 34664484
pii: S0031-0808.21.04541-9
doi: 10.23736/S0031-0808.21.04541-9
doi:

Substances chimiques

Immunologic Factors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-71

Auteurs

Anupam Dhasmana (A)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA.
School of Medicine, South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX, USA.
Department of Biosciences and Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, India.

Swati Dhasmana (S)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA.
School of Medicine, South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX, USA.

Sudhir Kotnala (S)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA.
School of Medicine, South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX, USA.

A Anukriti (A)

School of Liberal Arts and Sciences, Department of Biosciences, Mody University, Rajasthan, India.

Vivek K Kashyap (VK)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA.
School of Medicine, South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX, USA.

Poornima D Shaji (PD)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA.

Partha Laskar (P)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA.
School of Medicine, South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX, USA.

Sheema Khan (S)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA.
School of Medicine, South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX, USA.

Rinaldo Pellicano (R)

Unit of Gastroenterology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy.

Sharmila Fagoonee (S)

Institute of Biostructure and Bioimaging (CNR), Molecular Biotechnology Center, Turin, Italy.

Shafiul Haque (S)

Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia.
Bursa Uludağ University Faculty of Medicine, Görükle Campus, Nilüfer, Bursa, Turkey.

Murali M Yallapu (MM)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA.
School of Medicine, South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX, USA.

Subhash C Chauhan (SC)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA.
School of Medicine, South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX, USA.

Meena Jaggi (M)

School of Medicine, Department of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, USA - meena.jaggi @utrgv.edu.
School of Medicine, South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH